APM - Aptorum's subsidiary paths innovation to merge with Universal Sequencing Technology shares up 8.3%
2023-05-01 11:16:40 ET
- Aptorum Group ( NASDAQ: APM ) is up 8.3% after announcing a non-binding Letter of Intent to merge its subsidiary Paths Innovation Limited with Universal Sequencing Technology.
- Paths Innovation Limited, which is majority-owned by Aptorum, holds the PathsDx technology through its subsidiary Paths Diagnostics. This liquid biopsy Next-Generation Sequencing ( NGS ) technology is used for diagnosing infectious diseases.
- As part of the transaction, upon closing, Aptorum's subsidiary Aptorum Therapeutics will become a shareholder in the combined company.
- Press Release
For further details see:
Aptorum's subsidiary paths innovation to merge with Universal Sequencing Technology, shares up 8.3%